Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebocontrolled, parallel-group study
Coverage decisions, prior authorization criteria and diagnosis coding all key off the approved indication

RESEARCH AREAS Pan-ERR (ERR//) receptor binding and agonist activation mechanisms Transcriptional regulation of mitochondrial biogenesis pathways in cell models Modulation of oxidative phosphorylation and fatty-acid oxidation gene sets PGC-1/ERR signaling-axis interactions in cultured myocyte systems WHAT RESEARCHERS LOOK AT Receptor-binding affinity and isoform selectivity assays Reporter-gene transcriptional activation readouts in transfected cell lines qPCR/RNA-seq profiling of ERR target-gene expression in vitro Compound stability, solubility, and purity verification by HPLC and mass spectrometry QUICK SPECS Form: Capsule not for ingestion Net per capsule: 100mcg Count: 60 capsules per bottle Purity: 98% (HPLC) Identity: Confirmed by mass spectrometry Storage: Cool, dry conditions away from light IDENTITY BASICS Type: Synthetic small-molecule ERR agonist (non-peptide) Molecular Formula: CHClNO Molecular Weight: ~426.9 g/mol CAS: 2756409-79-1 SELECTED RESEARCH PubChem: SLU-PP-332 compound record PubMed: ERR agonist SLU-PP-332 studies PubMed: ERR and mitochondrial biogenesis PubMed: ERR oxidative metabolism regulation DISCLAIMER For laboratory research use only

This dual action leads to more effective and comfortable weight loss compared to other single-hormone treatments
It signals your brain that food has arrived, helps your pancreas release insulin at the right time, slows down stomach emptying, and helps keep blood sugar steady